<DOC>
	<DOCNO>NCT00386984</DOCNO>
	<brief_summary>A preliminary study show hormone-similar , growth-retarding drug octreotide prolong survival time patient primary liver cancer . Due methodological deficiency preliminary study result re-checked comparison octreotide pseudo-drug ( so-called placebo ) primarily regard survival time secondarily concern cost , side effect , patient cooperation quality life well specific condition tumor tissue group 108 patient primary liver cancer .</brief_summary>
	<brief_title>Hector-Study Evaluate Efficacy Octreotide Patients With Inoperable Hepatocellular Carcinoma</brief_title>
	<detailed_description>A pilot study show octreotide prolong survival time patient HCC . Due methodological deficiency result pilot study re-evaluated comparison octreotide versus placebo primarily regard global survival time secondarily concern cost , side effect , patient compliance quality life well Somatostatin receptor tumor tissue prognostic relevance group 108 patient hepatocellular carcinoma . An interim analysis do occurrence half event ( death ) . No significant effect could show .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inoperable patient histologically confirm HCC patient refuse surgery otherwise ( e.g . due advanced tumor stage ) applicable palliative local therapy ( e.g . PEI , TACE , RFTA ) . Age : 18 year old General : Patient symptomatic Cholecyst/Choledocholithiasis Patient severe psychiatric disease . Participation another clinical trial within last 4 week . Simultaneous participation another clinical examination . Legally incapacitated patient , able , understand nature , mean consequence study . Continuous drug alcohol abuse . Patient known HIV infection antiretroviral therapy . Patient controllable infection disease . Pregnancy . Study indicationspecific exclusion criterion : Secondary malignant tumor without complete remission . Secondary malignant tumor complete remission current adjuvant therapy . Preliminary current therapy tamoxifen Pretreatment HCC . Firsttime diagnosis &gt; 6 month inclusion study . Severe hepatic encephalopathy , refractory treatment . Patients operable HCC . Contraindication i.m . injection . Hypersensitivity octreotide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>hepatocellular carcinoma ; Sandostatin-LAR ; RCT</keyword>
</DOC>